ERAS
Erasca Inc

521
Mkt Cap
$783.04M
Volume
1.43M
52W High
$3.30
52W Low
$1.01
PE Ratio
-6.12
ERAS Fundamentals
Price
$2.78
Prev Close
$2.76
Open
$2.87
50D MA
$2.25
Beta
1.49
Avg. Volume
1.96M
EPS (Annual)
-$0.6914
P/B
2.25
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
HC Wainwright Issues Optimistic Estimate for Erasca Earnings
Erasca, Inc. (NASDAQ:ERAS - Free Report) - HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Erasca in a note issued to investors on Thursday, November 13th. HC Wainwright...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
HC Wainwright Forecasts Erasca's Q1 Earnings (NASDAQ:ERAS)
Erasca, Inc. (NASDAQ:ERAS - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Erasca in a research report issued to clients and investors...
MarketBeat·5d ago
News Placeholder
Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Guggenheim Analyst Says
Guggenheim lifted their target price on Erasca from $3.00 to $5.00 and gave the company a "buy" rating in a research report on Friday...
MarketBeat·5d ago
News Placeholder
Erasca (NASDAQ:ERAS) Issues Earnings Results, Hits Estimates
Erasca (NASDAQ:ERAS - Get Free Report) released its earnings results on Wednesday. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11...
MarketBeat·7d ago
News Placeholder
Erasca (NASDAQ:ERAS) Shares Up 8.3% - Time to Buy?
Erasca (NASDAQ:ERAS) Shares Up 8.3% - Should You Buy...
MarketBeat·7d ago
News Placeholder
Can Centene's Q3 Earnings Escape Industry's Cost Headwinds?
CNC braces for Q3 results as revenue growth may be offset by rising medical costs and shrinking Medicaid memberships.
Zacks·24d ago
News Placeholder
Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings?
THC's third-quarter results may show profit growth despite lower patient days and mixed hospital trends.
Zacks·28d ago
News Placeholder
Will Rising Costs Hurt HCA Healthcare Q3 Earnings? Key Estimates Here
HCA's Q3 earnings to witness solid revenue growth, but rising expenses may weigh on results.
Zacks·1mo ago
News Placeholder
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 26, 2024 USA News...
PR Newswire·11mo ago
News Placeholder
Erasca Inc. Poised for Growth: Buy Rating Maintained Amidst Promising Trial Updates and Solid Financials
Chris Shibutani, an analyst from Goldman Sachs, maintained the Buy rating on Erasca (ERAS Research Report). The associated price target was lower...
TipRanks Financial Blog·1y ago

Latest ERAS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.